Decrease of RBM4 indicates poor prognosis in patients with hepatocellular carcinoma after hepatectomy
RNA-binding motif 4 (RBM4) has been reported to play an important role in many human tumors such as lung cancer, breast cancer, ovarian cancer and gastric cancer by regulating alternative splicing and messenger RNA (mRNA) translation. However, little is known about the role of RBM4 in the developmen...
Gespeichert in:
| Veröffentlicht in: | OncoTargets and therapy 2017-01, Vol.10, p.339-345 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 345 |
|---|---|
| container_issue | |
| container_start_page | 339 |
| container_title | OncoTargets and therapy |
| container_volume | 10 |
| creator | Chen, Jian-Yao Liu, Li-Ping Xu, Jiang-Feng |
| description | RNA-binding motif 4 (RBM4) has been reported to play an important role in many human tumors such as lung cancer, breast cancer, ovarian cancer and gastric cancer by regulating alternative splicing and messenger RNA (mRNA) translation. However, little is known about the role of RBM4 in the development of hepatocellular carcinoma (HCC). This study aimed to investigate the expression of RBM4 in HCC tissues. Expression of RBM4 was detected by immunohistochemistry in 95 cases of HCC. Correlations of RBM4 expression with the overall survival and disease-free survival of HCC were also studied. Patients with high RBM4 expression had better overall survival rate and disease-free survival rate than those with low RBM4 expression ( |
| doi_str_mv | 10.2147/OTT.S125250 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5238762</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A534206478</galeid><sourcerecordid>A534206478</sourcerecordid><originalsourceid>FETCH-LOGICAL-c507t-864f1f272eb0b9d4bfc07fdcfe970048c21d2c904f4281d7ef9f9a221c6481253</originalsourceid><addsrcrecordid>eNptkt-L1DAQx4so3g998l0KghzIrsk0bdIX4Tx_wsmBrs8hm062OdqkJqly_71Zdj13RfKQTOYz32SGb1E8o2QJlPHXN6vV8huFGmryoDillItF01bk4cH5pDiL8ZaQphHAHhcnIGgloOanBb5DHVBFLL0pv779wkrrOqtVwlhO3odyCn7jfLQxJ8pJJYsuxfKXTX3ZY469xmGYBxVKrYK2zo-qVCZh2KVRJz_ePSkeGTVEfLrfz4vvH96vrj4trm8-fr66vF7omvC0EA0z1AAHXJN127G10YSbThtsOSFMaKAd6JYww3IHHUfTmlYBUN0wkSdQnRdvdrrTvB6x0_mvQQ1yCnZU4U56ZeVxxtlebvxPWUMleANZ4GIvEPyPGWOSo43bDpVDP0dJRVMBkIrxjL74B731c3C5PQnAoKFVy-q_1EYNKK0zPr-rt6Lysq4YkIZxkanlf6i8Ohyt9g6NzfdHBS8PCnpUQ-qjH-ZkvYvH4KsdqIOPMaC5HwYlcmsfme0j9_bJ9PPD-d2zf_xS_QZFCr82</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2242613945</pqid></control><display><type>article</type><title>Decrease of RBM4 indicates poor prognosis in patients with hepatocellular carcinoma after hepatectomy</title><source>Taylor & Francis Open Access</source><source>DOVE Medical Press Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>PubMed Central Open Access</source><creator>Chen, Jian-Yao ; Liu, Li-Ping ; Xu, Jiang-Feng</creator><creatorcontrib>Chen, Jian-Yao ; Liu, Li-Ping ; Xu, Jiang-Feng</creatorcontrib><description>RNA-binding motif 4 (RBM4) has been reported to play an important role in many human tumors such as lung cancer, breast cancer, ovarian cancer and gastric cancer by regulating alternative splicing and messenger RNA (mRNA) translation. However, little is known about the role of RBM4 in the development of hepatocellular carcinoma (HCC). This study aimed to investigate the expression of RBM4 in HCC tissues. Expression of RBM4 was detected by immunohistochemistry in 95 cases of HCC. Correlations of RBM4 expression with the overall survival and disease-free survival of HCC were also studied. Patients with high RBM4 expression had better overall survival rate and disease-free survival rate than those with low RBM4 expression (
<0.001,
=0.007, respectively). RBM4 expression, together with tumor numbers, capsular formation, vascular invasion and Barcelona clinic liver cancer (BCLC) stage, was an independent prognostic factor for overall survival rate and disease-free survival rate of HCC. Our data implicate RBM4 as a novel prognostic marker and a potential therapeutic target for HCC.</description><identifier>ISSN: 1178-6930</identifier><identifier>EISSN: 1178-6930</identifier><identifier>DOI: 10.2147/OTT.S125250</identifier><identifier>PMID: 28138257</identifier><language>eng</language><publisher>New Zealand: Dove Medical Press Limited</publisher><subject>Apoptosis ; Biotechnology ; Breast cancer ; Care and treatment ; Cellular proteins ; Development and progression ; Gene expression ; Genetic aspects ; Health aspects ; Hepatectomy ; Hepatitis ; Hepatocellular carcinoma ; Infections ; Liver cancer ; Liver cirrhosis ; Lung cancer ; Medical prognosis ; Medicine ; Original Research ; Ovarian cancer ; Patient outcomes ; Proteins ; Surgery ; Survival analysis ; Tumors ; Ultrasonic imaging</subject><ispartof>OncoTargets and therapy, 2017-01, Vol.10, p.339-345</ispartof><rights>COPYRIGHT 2017 Dove Medical Press Limited</rights><rights>2017. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2017 Chen et al. This work is published and licensed by Dove Medical Press Limited 2017</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c507t-864f1f272eb0b9d4bfc07fdcfe970048c21d2c904f4281d7ef9f9a221c6481253</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5238762/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5238762/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,3849,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28138257$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chen, Jian-Yao</creatorcontrib><creatorcontrib>Liu, Li-Ping</creatorcontrib><creatorcontrib>Xu, Jiang-Feng</creatorcontrib><title>Decrease of RBM4 indicates poor prognosis in patients with hepatocellular carcinoma after hepatectomy</title><title>OncoTargets and therapy</title><addtitle>Onco Targets Ther</addtitle><description>RNA-binding motif 4 (RBM4) has been reported to play an important role in many human tumors such as lung cancer, breast cancer, ovarian cancer and gastric cancer by regulating alternative splicing and messenger RNA (mRNA) translation. However, little is known about the role of RBM4 in the development of hepatocellular carcinoma (HCC). This study aimed to investigate the expression of RBM4 in HCC tissues. Expression of RBM4 was detected by immunohistochemistry in 95 cases of HCC. Correlations of RBM4 expression with the overall survival and disease-free survival of HCC were also studied. Patients with high RBM4 expression had better overall survival rate and disease-free survival rate than those with low RBM4 expression (
<0.001,
=0.007, respectively). RBM4 expression, together with tumor numbers, capsular formation, vascular invasion and Barcelona clinic liver cancer (BCLC) stage, was an independent prognostic factor for overall survival rate and disease-free survival rate of HCC. Our data implicate RBM4 as a novel prognostic marker and a potential therapeutic target for HCC.</description><subject>Apoptosis</subject><subject>Biotechnology</subject><subject>Breast cancer</subject><subject>Care and treatment</subject><subject>Cellular proteins</subject><subject>Development and progression</subject><subject>Gene expression</subject><subject>Genetic aspects</subject><subject>Health aspects</subject><subject>Hepatectomy</subject><subject>Hepatitis</subject><subject>Hepatocellular carcinoma</subject><subject>Infections</subject><subject>Liver cancer</subject><subject>Liver cirrhosis</subject><subject>Lung cancer</subject><subject>Medical prognosis</subject><subject>Medicine</subject><subject>Original Research</subject><subject>Ovarian cancer</subject><subject>Patient outcomes</subject><subject>Proteins</subject><subject>Surgery</subject><subject>Survival analysis</subject><subject>Tumors</subject><subject>Ultrasonic imaging</subject><issn>1178-6930</issn><issn>1178-6930</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNptkt-L1DAQx4so3g998l0KghzIrsk0bdIX4Tx_wsmBrs8hm062OdqkJqly_71Zdj13RfKQTOYz32SGb1E8o2QJlPHXN6vV8huFGmryoDillItF01bk4cH5pDiL8ZaQphHAHhcnIGgloOanBb5DHVBFLL0pv779wkrrOqtVwlhO3odyCn7jfLQxJ8pJJYsuxfKXTX3ZY469xmGYBxVKrYK2zo-qVCZh2KVRJz_ePSkeGTVEfLrfz4vvH96vrj4trm8-fr66vF7omvC0EA0z1AAHXJN127G10YSbThtsOSFMaKAd6JYww3IHHUfTmlYBUN0wkSdQnRdvdrrTvB6x0_mvQQ1yCnZU4U56ZeVxxtlebvxPWUMleANZ4GIvEPyPGWOSo43bDpVDP0dJRVMBkIrxjL74B731c3C5PQnAoKFVy-q_1EYNKK0zPr-rt6Lysq4YkIZxkanlf6i8Ohyt9g6NzfdHBS8PCnpUQ-qjH-ZkvYvH4KsdqIOPMaC5HwYlcmsfme0j9_bJ9PPD-d2zf_xS_QZFCr82</recordid><startdate>20170101</startdate><enddate>20170101</enddate><creator>Chen, Jian-Yao</creator><creator>Liu, Li-Ping</creator><creator>Xu, Jiang-Feng</creator><general>Dove Medical Press Limited</general><general>Taylor & Francis Ltd</general><general>Dove Medical Press</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20170101</creationdate><title>Decrease of RBM4 indicates poor prognosis in patients with hepatocellular carcinoma after hepatectomy</title><author>Chen, Jian-Yao ; Liu, Li-Ping ; Xu, Jiang-Feng</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c507t-864f1f272eb0b9d4bfc07fdcfe970048c21d2c904f4281d7ef9f9a221c6481253</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Apoptosis</topic><topic>Biotechnology</topic><topic>Breast cancer</topic><topic>Care and treatment</topic><topic>Cellular proteins</topic><topic>Development and progression</topic><topic>Gene expression</topic><topic>Genetic aspects</topic><topic>Health aspects</topic><topic>Hepatectomy</topic><topic>Hepatitis</topic><topic>Hepatocellular carcinoma</topic><topic>Infections</topic><topic>Liver cancer</topic><topic>Liver cirrhosis</topic><topic>Lung cancer</topic><topic>Medical prognosis</topic><topic>Medicine</topic><topic>Original Research</topic><topic>Ovarian cancer</topic><topic>Patient outcomes</topic><topic>Proteins</topic><topic>Surgery</topic><topic>Survival analysis</topic><topic>Tumors</topic><topic>Ultrasonic imaging</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chen, Jian-Yao</creatorcontrib><creatorcontrib>Liu, Li-Ping</creatorcontrib><creatorcontrib>Xu, Jiang-Feng</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>OncoTargets and therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chen, Jian-Yao</au><au>Liu, Li-Ping</au><au>Xu, Jiang-Feng</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Decrease of RBM4 indicates poor prognosis in patients with hepatocellular carcinoma after hepatectomy</atitle><jtitle>OncoTargets and therapy</jtitle><addtitle>Onco Targets Ther</addtitle><date>2017-01-01</date><risdate>2017</risdate><volume>10</volume><spage>339</spage><epage>345</epage><pages>339-345</pages><issn>1178-6930</issn><eissn>1178-6930</eissn><abstract>RNA-binding motif 4 (RBM4) has been reported to play an important role in many human tumors such as lung cancer, breast cancer, ovarian cancer and gastric cancer by regulating alternative splicing and messenger RNA (mRNA) translation. However, little is known about the role of RBM4 in the development of hepatocellular carcinoma (HCC). This study aimed to investigate the expression of RBM4 in HCC tissues. Expression of RBM4 was detected by immunohistochemistry in 95 cases of HCC. Correlations of RBM4 expression with the overall survival and disease-free survival of HCC were also studied. Patients with high RBM4 expression had better overall survival rate and disease-free survival rate than those with low RBM4 expression (
<0.001,
=0.007, respectively). RBM4 expression, together with tumor numbers, capsular formation, vascular invasion and Barcelona clinic liver cancer (BCLC) stage, was an independent prognostic factor for overall survival rate and disease-free survival rate of HCC. Our data implicate RBM4 as a novel prognostic marker and a potential therapeutic target for HCC.</abstract><cop>New Zealand</cop><pub>Dove Medical Press Limited</pub><pmid>28138257</pmid><doi>10.2147/OTT.S125250</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1178-6930 |
| ispartof | OncoTargets and therapy, 2017-01, Vol.10, p.339-345 |
| issn | 1178-6930 1178-6930 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5238762 |
| source | Taylor & Francis Open Access; DOVE Medical Press Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; PubMed Central Open Access |
| subjects | Apoptosis Biotechnology Breast cancer Care and treatment Cellular proteins Development and progression Gene expression Genetic aspects Health aspects Hepatectomy Hepatitis Hepatocellular carcinoma Infections Liver cancer Liver cirrhosis Lung cancer Medical prognosis Medicine Original Research Ovarian cancer Patient outcomes Proteins Surgery Survival analysis Tumors Ultrasonic imaging |
| title | Decrease of RBM4 indicates poor prognosis in patients with hepatocellular carcinoma after hepatectomy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T00%3A18%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Decrease%20of%20RBM4%20indicates%20poor%20prognosis%20in%20patients%20with%20hepatocellular%20carcinoma%20after%20hepatectomy&rft.jtitle=OncoTargets%20and%20therapy&rft.au=Chen,%20Jian-Yao&rft.date=2017-01-01&rft.volume=10&rft.spage=339&rft.epage=345&rft.pages=339-345&rft.issn=1178-6930&rft.eissn=1178-6930&rft_id=info:doi/10.2147/OTT.S125250&rft_dat=%3Cgale_pubme%3EA534206478%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2242613945&rft_id=info:pmid/28138257&rft_galeid=A534206478&rfr_iscdi=true |